• 150年来西班牙知识产权领域的领航者

  • 艾萨博睿第8届年度大会

    艾萨博睿第8届年度大会

    10/04/2015 - Espacio CÓMO

  • Leaders in intangible asset management and legal advisory services

  • We defend authors, artists, and makers of all intellectual creations

  • Different paths, different countries, … different solutions

最新消息



Elzaburu 150 years


Elzaburu in Busines TV

新闻

博客

  • ​爱立信因苹果未向其支付许可费而将苹果告上法庭
    爱立信分别在英国,德国和荷兰发起了对苹果的诉讼。控诉理由为苹果未能支付其技术许可费用。

    瑞典电信设备制造商爱立信称,尽管许可已经到期,苹果仍然在使用其专利技术。早些时候爱立信曾经试图通过仲裁谈判与苹果将该纠纷解决,但如今此举动已无效,爱立信最终决定将苹果告上法庭。苹果公司对此诉讼还未作出回应。

    New judgment by the CJEU concerning SPCs for combinations of pharmaceutical products

    The Court of Justice of the European Union has issued new judgment interpreting Articles 1, 3, and 13 of Regulation (EC) No. 469/2009 concerning the supplementary protection certificate (SCP) for medicinal products.

    The judgment (Case C-577/13) was issued in the context of a dispute between the Actavis and Boehringer Ingelheim pharmaceutical companies. The question referred to the CJEU for a preliminary ruling basically comes down to whether an SPC may be sought for a combination of two products included in the claims after the initial grant of the basic patent, subsequent to amendment of the said patent. The combination was composed of: (i) an active ingredient claimed as the sole subject matter of the invention, for which the holder had already obtained a first SPC (telmisartan) and (ii) a second substance (hydrochlorothiazide) within the public domain.

    New judgment by the CJEU concerning SPCs for combinations of pharmaceutical products

    The Court of Justice of the European Union has issued new judgment interpreting Articles 1, 3, and 13 of Regulation (EC) No. 469/2009 concerning the supplementary protection certificate (SCP) for medicinal products.

    The judgment (Case C-577/13) was issued in the context of a dispute between the Actavis and Boehringer Ingelheim pharmaceutical companies. The question referred to the CJEU for a preliminary ruling basically comes down to whether an SPC may be sought for a combination of two products included in the claims after the initial grant of the basic patent, subsequent to amendment of the said patent. The combination was composed of: (i) an active ingredient claimed as the sole subject matter of the invention, for which the holder had already obtained a first SPC (telmisartan) and (ii) a second substance (hydrochlorothiazide) within the public domain.

    微博

    © ELZABURU 2015 - Miguel Ángel, 21 - 28010 Madrid, España (Spain)  - Teléfono: +34-91 700 9400 - Fax: +34-91 319 3810 - elzaburu@elzaburu.es

    We have published a new Cookies Policy explaining what Cookies are and how we use them on our Website. We use third-party Cookies to analyse user browsing and predetermine the user's language. If you wish to know more about Cookies, their functions and/or disable them, please read our Cookies Policy. Bear in mind that some parts of the Website will not function correctly if Cookies are disabled.
    By continuing to use this Website, you are consenting to the use of Cookies.
    Depending on whether or not you consent to the use of cookies on this Website, you will be sent an additional Cookie so that your choice is remembered and you do not have to accept the use of Cookies every time you access the Elzanet Website.